What Happened?
Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 9.6% in the pre-market session after the company reported impressive fourth-quarter results, exceeding analysts' sales and EPS estimates. Total revenue grew 16% y/y fueled by strong demand for Voxzogo, which saw a 42% jump in sales, and a steady 9% increase in its Enzyme Therapies segment. Improved profitability also played a key role, with GAAP net income soaring more than fivefold. Looking ahead, management expects another year of double-digit revenue and earnings growth in 2025, with a projected 10% increase in total revenue at the midpoint of guidance. Overall, the quarter reflected strong execution, with standout performances in key growth areas and clear momentum heading into the first half of 2025.
The shares closed the day at $68.71, up 4.6% from previous close.
Is now the time to buy BioMarin Pharmaceutical? Access our full analysis report here, it’s free .
What The Market Is Telling Us
BioMarin Pharmaceutical’s shares are not very volatile and have only had 5 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
BioMarin Pharmaceutical is up 5.3% since the beginning of the year, but at $70 per share, it is still trading 25.4% below its 52-week high of $93.84 from August 2024. Investors who bought $1,000 worth of BioMarin Pharmaceutical’s shares 5 years ago would now be looking at an investment worth $780.73.
Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next .
